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Abstract
The purpose of this study was to assess the effects of transforming growth factor beta (TGF-b) inhibitor peptides (P17 &
P144) on early laser-induced choroidal neovascularization (LI-CNV) lesions in rats, two weeks after laser CNV induction.
Seventy-one Long Evans rats underwent diode laser application in an established LI-CNV model. Baseline fluorescein
angiography (FA) was performed 14 days following laser procedure, and treatments were administered 16 days post-laser
application via different administration routes. Intravenous groups included control (IV-Control), P17 (IV-17), and P144 (IV-
144) groups, whereas intravitreal groups included P17 (IVT-17), P144 (IVT-144), and a mixture of both peptides (IVT-17+144)
(with fellow eyes receiving vehicle alone). CNV evolution was assessed using FA performed weekly for four weeks after
treatment. Following sacrifice, VEGF, TGF-b, COX-2, IGF-1, PAI-1, IL-6, MMP-2, MMP-9, and TNF-a gene expression was
assessed using RT-PCR. VEGF and p-SMAD2 protein levels were also assessed by western-blot, while MMP-2 activity was
assessed with gelatin zymography. Regarding the FA analysis, the mean CNV area was lower from the 3rd week in IVT-17 and
IVT-144 groups, and also from the 2nd week in IVT-17+144. Biochemical analysis revealed that gene expression was lower for
VEGF and COX-2 genes in IV-17 and IV-144 groups, VEGF gene in IVT-17+144 group and MMP-2 gene in IVT-17 and IVT-144
groups. VEGF protein expression was also decreased in IV-17, IV-144, IVT-17 and IVT-144, whereas pSMAD-2 levels were
lower in IV-17, IV-144 and IVT-17+144 groups. Zymogram analysis revealed decreased MMP-2 activity in IV-17, IV-144, IVT-17
and IVT-144 groups. These data suggest that the use of TGF-b inhibitor peptides (P17 & P144) decrease the development of
early CNV lesions by targeting different mediators than those typically affected using current anti-angiogenic therapies. Its
potential role in the treatment of early CNV appears promising as a single therapy or adjuvant to anti-VEGF drugs.
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Introduction
Choroidal neovascularization (CNV) is the final common
process for multiple retinal diseases in which the development of
abnormal neovascular tissue with increased permeability produces
fluid leakage into the outer subretinal space in the macula [1–5].
In naı¨ve lesions that remain untreated, CNV development is
followed by fibrous processes that end in progressive macular
destruction, leading to substantial loss of autonomy and quality of
life [6,7]. This multifactorial process involves multiple molecules in
complex networks, the study of which has become a major area of
research in recent years. In normal eyes, the retinal pigment
epithelium (RPE) and other cells maintain a global antiangiogenic
state in the resting retina. In CNV, upregulation of proangiogenic
molecules such as vascular endothelial growth factor (VEGF) (the
main factor related with angiogenesis), platelet-derived growth
factor (PDGF), angiopoietin, and b-fibroblast growth factor (b-
FGF), and decreased production of angiogenic inhibitors, such as
pigment epithelium-derived factor (PEDF) and thrombospondin-1,
produces an imbalance that favours neovascular growth [8–10].
The overexpression of VEGF in CNV has been demonstrated and
this molecule has become the target of current therapies [11–14].
Recent studies have been directed towards other mediators related
with VEGF-upregulation, among which is transforming growth
factor beta (TGF-b)[15,16]. TGF-b is a pleiotropic molecule that
participates in both angiogenesis and fibrotic processes, and its
presence has been demonstrated in surgically excised human
neovascular membranes [17]. More recently, studies using human
RPE cell cultures have reported that TGF-b significantly enhances
VEGF secretion and also exerts a strong effect through
extracellular matrix remodelling [15,16,18]. A synergistic associ-
ation with b-FGF and tumor necrosis factor-alpha (TNF-a) over
VEGF transcription has been reported, suggesting that TGF-b
may work in concert with other cytokines in VEGF upregulation
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[19]. These findings led us to speculate that selective blockade of
TGF-b would abate CNV development, a hypothesis recently
confirmed in a study performed with two anti-TGF-b inhibitor
peptides in a laser induced CNV model [20]. In this study, we
evaluated the effect of these peptides on CNV induction, with
treatments administered 48 hours after laser application. Howev-
er, CNV development occurs in different stages, each of which is
mediated by different growth factors and cellular types. Therefore,
separate consideration of each stage should be considered for the
development of optimal treatment strategies. Whereas some
cytokines participate in several stages of CNV formation, as well
as in a number of disparate but simultaneous processes, these
molecules appear as the ideal target for CNV therapies. The
multiple roles played by TGF-b suggest that its blockage may not
only decrease the angiogenic process related with CNV, but may
also affect other pathways related to progression of the disease.
To test this hypothesis, in this new study design we assessed the
effect of the anti-TGF-b peptides in early CNV lesions 16 days
after laser induction, in contrast to our previous study in CNV
induction in which treatments were administered 48 hours post
laser [20]. Whereas mostly of the studies in the literature have
evaluated therapies administered around the time of lesion
induction, recently a different behaviour of some treatments in
early lesions at a later stage has been reported [21]. In the current
work, the 16 days period of time after laser induction corresponds
Figure 1. Fluorescein angiography (FA) images of all study
groups. Left-image: Baseline, right-image: 4 weeks post-treatment. A:
Intravenous control group (IV-Control). B: Intravenous P17 group (IV-
17). C: Intravenous P144 group (IV-144). D: Intravitreal P17 group (IVT-
17). E: Intravitreal P144 group (IVT-144). F: Intravitreal P17+P144 group
(IVT-17+144).
doi:10.1371/journal.pone.0065434.g001
Figure 2. Mean CNV areas assessed by fluorescein angiographies in all study groups (measured in pixels). Differences between treated
and untreated eyes. Top left: Intravenous Controls vs Intravenous P17 vs Intravenous P144 (IV-Control vs IV-17 vs IV-144); top right: Intravitreal P17
(IVT-17); bottom left: Intravitreal P144 (IVT-144); bottom right: Intravitreal P17+P144 (IVT-17+144). (NS: Not significant; * p,0.05; ** p,0.01).
doi:10.1371/journal.pone.0065434.g002
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with the peak of CNV formation previously reported in our
established laser-induced CNV animal model [22] and aims to
reproduce early lesions similar to those seen in clinical practice.
We selected the two specific TGF-b inhibitor peptides employed
in our previous study - P17 and P144 - at their most effective doses
and we also include a recently developed intravenous solution of
P144. Administration of these peptides is safe and has demon-
strated a strong TGF-b inhibitory effect in different animal
models, cellular cultures and in vivo angiogenesis assays in a
synthetic matrix [23–28]. P17 inhibits TGF-b with a relative
binding affinity of 100% for TGF-b1, 80% for TGF-b2 and 30%
for TGF-b3 in surface plasmon resonance (SPR) assays [29],
whereas similar binding assays are being currently carried out for
P144 (unpublished data).
Figure 3. Real time-Polymerase Chain Reaction (Rt-PCR) results. Differences between treated and untreated eyes in all study groups (Mean+/
2SD; 5 eyes/study group). Top left: IV-Control vs IV-17. Top right: IV-Control vs IV-144. Middle left: IVT-17. Middle right: IVT-144. Bottom left: IVT-
17+144. (NS: Not significant; * p,0.05; ** p,0.01).
doi:10.1371/journal.pone.0065434.g003
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Materials and Methods
Study Animals
The current study was conducted according to the Association
for Research in Vision and Ophthalmology (ARVO) Resolution
on the Use of Animals in Ophthalmic and Vision Research and
approved by the Ethics Committee for Animal Research of the
University of Navarra. Seventy-one pigmented-retina Long Evans
male rats (age, 12 weeks; weight, approximately 320 grams) were
randomized in three intravenous (IV-Control, IV-17, IV-144) and
three intravitreal (IVT-17, IVT-144, IVT-17+144) study groups.
Rats were intraperitoneally anesthetized with a mixture of
ketamine (Imalgene 1000) (75 mg/kg) and Xylacine (Rompun
2%) (10 mg/kg) for all procedures. Injections were performed with
a 1 mL syringe and a 25-gauge needle.
Diode Laser-Induced CNV Model
All study eyes were dilated with tropicamide 1% eye drops and
eight to ten laser photocoagulation sites were placed concentrically
around the optic disc for induction of CNV lesions. A diode laser
(810 nm) connected to a slit lamp was used with a relative potency
scale of 250 mW, an exposure time of 0.05 seconds, and a spot
Figure 4. Western blotting for vascular endothelial growth factor (VEGF) expression in RPE in intravenous groups (left) and
intravitreal groups (right). Bars represent mean 6 SEM of percentage of arbitrary units (AU) vs. control (Total protein loaded: 8 mg; 5–6 eyes/
group). (* p,0.05).
doi:10.1371/journal.pone.0065434.g004
Figure 5. Western blotting for phosphorylated SMAD-2 (pSMAD-2) expression in RPE in intravenous groups (left) and intravitreal
groups (right). Bars represent mean 6 SEM of percentage of arbitrary units (AU) vs control (Total protein loaded: 8 mg; 5–6 eyes/group).(* p,0.05;
** p,0.01).
doi:10.1371/journal.pone.0065434.g005
TGF-b Inhibition Reduces Progression of Early CNV
PLOS ONE | www.plosone.org 4 May 2013 | Volume 8 | Issue 5 | e65434
size of 75 mm as established by protocol [22]. Laser spots were
focused with crystal covers to avoid laser beam dispersion. Bubble
formation confirmed the rupture of Bruchs membrane. Laser
rupture sites which developed haemorrhage or subretinal bleeding
at the time of laser application were excluded from analysis. The
mean leakage area of CNV lesions that developed at laser
photocoagulation sites was then assessed at each time point.
Differences between treated and control eyes for each study group
were then analyzed.
Study Groups
Intravenous Treatment Groups. Three intravenous groups
were included in the study, control, P17 and P144 groups. The
intravenous control group (IV-Control) received five intravenous
injections of 0.2 mL of saline every 72 hours over 2 weeks,
representative of natural laser-induced CNV evolution. Both
intravenous P17 and P144 groups (IV-17 and IV-144 respectively)
received five intravenous injections of 0.2 ml of P17 (1 mg/ml) or
P144 (1 mg/ml) suspended in 0.2 mL of saline (P17) or carbonate
(P144), every 72 hours over 2 weeks. Nine rats were included in
the IV-Control group, 10 rats were included in the IV-17 group,
and 10 rats were included in the IV-144 group.
Intravitreal Treatment Groups. Three groups were in-
cluded; P17, P144 and a mixture of both peptides P17+P144. The
dose and concentration of each peptide intravitreally injected was
as follows: P17 (IVT-17; 20 mg/ml), P144 (IVT-144; 3 mg/ml)
and P17+P144 (IVT-17+144; 20 & 3 mg/ml respectively). These
rats received a single dose of 7 ml of peptide solution in the treated
eye and 7 ml of its respective vehicle in the fellow eye of the same
animal. Whereas the hydrophilic P17 peptide was suspended in
saline, the hydrophobic P144 peptide and the mixture of both
peptides were suspended in a 75% of dimethyl sulfoxide saline
solution. Fourteen rats in IVT-17, 12 rats in IVT-144 and 16 rats
in IVT-17+144 were included in the study groups.
Injection Procedures
Treatments were administered 16 days after laser application in
all study groups. Intravenous injections were performed with 1 mL
syringes and 30G needle in the tail vein. Intravitreal injections
were performed with high-precision Hamilton syringes (Gastight
1702LT Hamilton Co., Reno, NV) and 30 gauge needles.
Injection sites were located 1 mm posterior to the corneoscleral
limbus. A single 7 ml injection of different peptide concentrations
was administered in the treated eye and the same volume of
vehicle solution in the fellow eye of the same animal (intravitreal
controls) in all intravitreal study groups (IVT-17, IVT-144, IVT-
17+144). The treatment eye was randomly selected for each rat.
Peptides
P144 (TSLDASIIWAMMQN), a hydrophobic peptide derived
from the sequence of the extracellular region of type III receptor
for TGF-b (Betaglycan, amino acids 730–743) [24], and P17
(KRIWFIPRSSWYERA), a soluble hydrophilic peptide identified
using a random phage display peptide library [25], were
synthesized by the solid phase method using the Fmoc alternative
by PolyPeptide Laboratories (Strasbourg, France)[30,31]. Peptides
were at least 95% pure as per HPLC.
Fluorescein Angiography (FA)
Images were obtained using a digital-adapted Retinograph
(Topcon TRC-50FX, Topcon Inc., Tokyo, Japan). For FA
evaluations, 0.2 mL of intravenous sodium fluorescein 2%
(200 mL/kg) was administered into the tail vein 2 minutes before
the images were captured (Figure 1). Digital FA images were
converted to TIFF files with Adobe PhotoshopH 7.0 software
(Adobe Inc., San Jose, CA, USA), and CNV leakage area was
calculated measuring the pixel area within the best-fitting polygon
of each rupture site [32] using the ‘‘shape definition’’ tool of
ImageQuantTLH (Amersham Biosciences, Uppsala, Sweden)
software by two independent, trained, masked observers (JZV,
SR). Mean CNV area was determined for every study group and
timepoint. FA was performed 2 weeks after laser induction
(baseline) and weekly post-treatment injection for 4 consecutive
weeks to assess the CNV evolution in all study groups.
Figure 6. Gelatin zymography assay for matrix metalloproteinase-2 (MMP-2) activity in RPE homogenates from intravenous groups
(left) and intravitreal groups (right). Bars represent mean6 SEM of percentage of arbitrary units (AU) vs. control (Total protein loaded: 8 mg; 5–6
eyes/group). (* p,0.05).
doi:10.1371/journal.pone.0065434.g006
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Quantitative Real time-Polymerase Chain Reaction (RT-
PCR)
Total RNA was isolated from rat retina using ABI PRISMTM
6100 Nucleic Acid PrepStation (Life technology, Carlsbad,
California, USA). 1000 ng of each mRNA was reverse transcribed
with the qScript cDNA Supermix kit (Quanta Biosciences Inc.,
Gaithersburg, MD, USA) using 2720 Thermal cycler (Life
technology, Carlsbad, California, USA). Nine pre-designed and
validated gene-specific TaqMan Gene Expression Assays from the
inflammation and vascularization pathways (Interleukin (IL)-6,
MMP-2, MMP-9, TNF-a, COX-2, VEGF, TGF-b, TNF-a and
PAI-1) from Applied Biosystem were used for quantitative real-
time RT-PCR in ABI Prism 7300 real-time PCR system (Applied
Biosystems). For further statistical evaluations the level of applied
housekeeping gene (ACTB) was used as endogenous control for
data normalization. Relative quantification studies were made
from collected data (threshold cycle numbers, referred as Ct) with
7300 System SDS software 1.3 (Applied Biosystems). Relative
quantity (RQ) of the gene specific mRNA was calculated by
DataAssist v 2.0.
Western blotting for vascular endothelial growth factor
(VEGF) and phosphorylated SMAD-2
Fivemg of RPE-choroid homogenates were mixed with Laemmli
buffer (Bio-Rad), boiled for 5 min and separated on 10–12% SDS-
PAGE gels and transferred to a nitrocellulose membrane. After
blocking with 5% skimmed milk (w/v), 0.1% Tween-20 (w/v) in
TBS (1 hour, RT) membranes were exposed to the primary
antibody anti-VEGF (0.2 mg/mL, monoclonal anti-VEGF, Santa
Cruz Biotechnology Inc., Santa Cruz, CA) at RT for 1 hour
followed by incubation at RT for 1 hour with a horseradish
peroxidase-conjugated goat anti-mouse antibody (sc2005; 0.4 mg/
mL, Santa Cruz Biotechnology Inc.). Membranes were tested for
anti-Smad2, phospho-specific (Chemicon-Millipore, Billerica, MA)
overnight at 4uC (0.5 mg/ml) followed by incubation at RT for
2 hours with a horseradish peroxidase-conjugated goat anti-rabbit
antibody (sc2054; 0.4 mg/mL, Santa Cruz Biotechnology Inc.).
Signals were detected with an enhanced chemoluminescence
(ECL) kit (ECL Western blotting detection kit, GE Healthcare,
Fairfield, CT) and captured with ImageQuant 400 (GE Health-
care). The relative intensities of the immunoreactive bands were
analyzed with ImageQuantTL software (GE Healthcare). The
loading was verified by Ponceau S red and the same blot was
stripped and reblotted with an anti-ß-actin monoclonal antibody
(Sigma-Aldrich) to normalize the VEGF and pSMAD-2 levels.
Gelatin zymography assay for matrix metalloproteinase-2
(MMP-2) activity
MMP-2 activity was quantified by gelatin zymography on RPE-
choroid homogenates. Fivemg of total protein from homogenate
supernatants were mixed with non-reducing sample buffer (Bio-
Rad) and electrophoresed directly on 9% SDS-polyacrylamide gels
containing 0.1% gelatin (w/v, from porcine skin, Sigma). Gels
were washed 4 times for 20 minutes at room temperature in a
2.5% (v/v) Triton X-100 solution, transferred to a Zymogram
development buffer (Bio-Rad) and incubated for 18 hours at 37
uC. Proteins were fixed with 50% methanol/7% acetic acid for 15
minutes and washed (6 times of 5 minutes each) with distilled
water. After that, gels were stained for 1 hour with GelCode Blue
Stain Reagent (Pierce, Rockford, USA) counterstained with
distilled water and then were analyzed with ImageQuant TL
(GE Healthcare) after densitometric scanning of the gels. The
active MMP-2/(active MMP-2+proMMP-2) intensity ratio desig-
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nated as the MMP-2 activation ratio. Each zymography assay was
repeated at least three times to ensure accuracy.
Statistical Analysis
Differences in the intravenous treatment groups were assessed
with one-way Analysis of Variance (ANOVA) test and indepen-
dent Student’s t-test with equal variance. Differences between
treated and control eyes in the intravitreal treatment groups were
assessed with paired Students t-test with equal variance or
Wilcoxons test in cases in which non-parametric tests were
required. P,0.05 was considered statistically significant (all
statistical analysis performed using SPSS 15.0 software, SPSS
Inc., Chicago, IL).
Results
Fluorescein Angiography
The mean CNV area determined for all study groups is
summarized in Table 1. In the intravenous treatment groups, no
significant differences were found in any of the studied groups. In
the intravitreal study groups, mean CNV areas in IVT-17 and
IVT-144 groups showed statistically significant differences be-
tween controls and treated eyes from the 3rd week. In the IVT-
17+144 group, statistically significant differences were found from
the 2nd week in treated eyes compared to their respective controls
(Figure 2).
Quantitative Real time-Polymerase Chain Reaction (RT-
PCR)
Results obtained from all study groups are shown in Figure 3.
Significant differences were obtained in VEGF and COX-2 genes
in both IV-17 and IV-144 study groups compared to IV-Control
group. None of the other studied genes were significantly different
in the intravenous study groups. In the intravitreal study groups,
significant differences were obtained in MMP-9 gene in treated
eyes of IVT-17 and IVT-144 groups compared to their respective
controls. No significant differences were obtained in other genes
for these groups. In the IVT-17+144 group, differences were
significant in VEGF gene between treated and control eyes. All
these data are presented in Table 2.
Western blotting for vascular endothelial growth factor
(VEGF) and phosphorylated SMAD-2
Western Blot results for mean VEGF and pSMAD-2 protein
levels in treated and control eyes for all study groups are
summarized in Tables 3 and 4. Mean VEGF protein expression
was significantly lower in the IV-17, IV-144, IVT-17 and IVT-144
treated eyes compared to control eyes (Figure 4). No significant
differences were found in the other groups. Mean pSMAD-2
protein levels were significantly lower in the IV-17, IV-144 and
Table 2. Real time Polymerase Chain Reaction.
IV-control vs IV-17 IV-control vs IV-144 IVT-17 IVT-144 IVT-17&144
Assay Type (RQ) (P-Value) (RQ) (P-Value) (RQ) (P-Value) (RQ) (P-Value) (RQ) (P-Value)
b actin
Selected
Control 1 NA 1 NA 1 NA 1 NA 1 NA
IL6 Target 1.102 NS 0.4556 NS 0.6928 NS 0.520 NS 1.043 NS
MMP-2 Target 0.956 NS 0.8336 NS 0.8545 NS 1.529 NS 1.198 NS
MMP-9 Target 0.6876 NS 0.4876 NS 0.5007 ,0.01** 0.4922 ,0.05* 1.030 NS
TNF-a Target 1.152 NS 1.152 NS 0.8729 NS 1.806 NS 0.7556 NS
COX-2 Target 0.3651 ,0.05* 0.3051 ,0.05* 1.268 NS 0.9001 NS 1.010 NS
IGF-1 Target 0.5891 NS 0.2391 NS 0.7463 NS 0.9153 NS 0.7339 NS
PAI-1 Target 0.3559 NS 0.0379 NS 2.114 NS 0.5484 NS 0.5913 NS
TGF-b Target 1.213 NS 0.7399 NS 0.7150 NS 0.8074 NS 0.8545 NS
VEGF Target 0.4386 ,0.05* 0.3636 ,0.05* 0.9675 NS 0.861 NS 0.5746 ,0.05*
Results are expressed as specific gene Relative Quantity (RQ) and p-value, b-Actin was selected as a control gene (5 eyes/group). Significance level: p,0.05. (NS: Not
significant; *:p,0.05 ; **:p:,0.01; NA: Not analyzed).
doi:10.1371/journal.pone.0065434.t002
Table 3. VEGF protein expression, pSMAD-2 protein levels
and MMP-2 activity in RPE homogenates - Intravitreal groups.
IVT-17 IVT-144 IVT-17+144
Control Treated Control Treated Control Treated
VEGF 100620 90620* 100615 88614* 100617 98614
pSMAD-2 100615 108613 100618 100614 100616 77612**
MMP-2
activity
100616 89612* 100613 84612* 100622 97618
Data are shown as mean 6 SEM of percentage of arbitrary units (AU) vs control
eye. (*p,0.05 and **p,0.01).
doi:10.1371/journal.pone.0065434.t003
Table 4. VEGF protein expression, pSMAD-2 protein levels
and MMP-2 activity in RPE homogenates - Intravenous groups.
Control IV-17 IV-144
VEGF 100611 6466* 7463*
pSMAD-2 100612 8164* 8765*
MMP-2 activity 10065 7164* 6964*
Data are shown as mean 6 SEM of percentage of arbitrary units (AU) vs control
group. (*p,0.05).
doi:10.1371/journal.pone.0065434.t004
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IVT-17+144 groups (Figure 5). None of the other study groups
showed significant differences between treated and control eyes.
Gelatin zymography assay for matrix metalloproteinase-2
(MMP-2) activity
MMP-2 activity levels were significantly lower in both
intravenous treatment groups IV-17 and IV-144 compared to
controls. In the intravitreal study groups, active MMP-2 levels
were significantly lower in IVT-17 and IVT-144 study groups
(Figure 6). No differences were observed in the IVT-17+144
group. These results are presented in Tables 3 and 4.
Discussion
The results obtained in our study demonstrate that peptides P17
and P144 reduce early CNV progression in a laser-induced rat
model. This is achieved through downregulation of VEGF and
TGF-b, but also by affecting other mediators involved in the
angiogenic process, such as COX-2, MMP-2 and MMP-9. These
findings suggest that TGF-b inhibition may be a novel therapeutic
approach, different to that of current treatments for early CNV
lesions.
CNV is a complex process that develops in several stages.
Different growth factors and cellular types are important in each
stage of the pathogenesis of CNV and similarities with wound
healing processes have been thoroughly described [10,33,34]. The
process starts in a favorable environment, commonly with
hypoxia, defects in Bruchs membrane, and increased oxidative
stress [35]. In these conditions, a pro-inflammatory state is created
by the release of interleukins (e.g., IL-6 and IL-8) and important
growth factors (e.g., MCP-1 and TGF-b) from RPE cells [36,37].
These cytokines have a strong chemotactic effect over macro-
phages, neutrophils and platelets, leading to their infiltration of the
area and subsequent enhancement of the early response by acting
as a complementary source of growth factors [34,38–41]. During
this recruitment, a second stage begins with prominent angiogen-
esis and fibrotic processes. The main growth factors involved in
angiogenesis are VEGF, angiopoietins, MCP-1, b-FGF and TGF-
b, which are frequently over-expressed at this stage through
complex up-regulation pathways that involve simultaneously
several of these mediators, whereas angiogenesis inhibitors such
as PEDF or thrombospondin are decreased [10,16–18]. Concom-
itantly, fibrosis is directed by PDGF, TGF-b, connective tissue
growth factor (CTGF) and IGF, leading to incipient tissue
regeneration processes in the lesion margins. Finally, the last
stage of CNV is the scar tissue formation phase, in which processes
of collagen remodelling and scar contraction are mediated by
FGF, IGF, CTGF and especially TGF-b [10,15–18]. In this stage,
the processes of degradation, synthesis and extracellular matrix
remodelling are directed by metalloproteinases such as MMP-2
and MMP-9, and its role in CNV has been described and
highlighted by recent studies [42]. The multiple roles played by
TGF-b and its relations with other growth factors implicated in the
different stages of CNV development led us to evaluate the effect
of its inhibition in early CNV lesions [15–19].
The results obtained with both peptides in the current study
have been promising. Fluorescein angiography analysis showed
decreased mean leakage area in all treated groups compared to
controls. Although this decrease did not reach the significance
level in intravenous groups, differences observed in all intravitreal
study groups were significant suggesting an inhibitory effect over
fluorescein leakage from laser-induced CNV lesions. Results of
biochemical analyses suggested that both peptides behaved in a
similar fashion for both intravenous and intravitreal administra-
tion. These findings suggest that the pattern of TGF-b inhibition is
similar with the two peptides and depends on the administration
route, affecting the same mediators in a reproducible way in
agreement with previous studies that found similar activity over
TGF-b in in-vitro assays [26]. To explain this different behaviour,
future pharmakodynamic studies should be directed to assess the
duration of peptides at intravitreal or intravenous level. Moreover,
the role of the hematoretinal barrier and its effect over the
diffusion characteristics of the peptides over the retinal structures
has also to be addressed.
The inhibition of VEGF gene expression and decreased VEGF
protein expression observed are consistent with our previous study
that reported effective downregulation of VEGF with both
peptides. These findings confirm that both P17 and P144 peptides
may have an antiangiogenic role in CNV treatment affecting the
main target of current treatments through TGF-b inhibition.
However, two exceptions were observed in our study. In the
intravitreal peptide groups no significant differences were found in
VEGF gene expression, and intravitreal mixture of both peptides
showed differences in VEGF gene expression but not in VEGF
protein expression. Whereas the type of study design and more
concisely the 6 weeks time from laser induction to eye collection
may explain the first, we suggest that joint administration of both
peptides may affect its properties and may explain differences
compared to single peptide injection. However, it is unclear how
this change is produced and again pharmacokinetic studies should
be directed to analyse these results. Decreased COX-2 gene
expression observed suggests an inhibitory effect of the peptides
over the inflammatory process that underlies CNV, and
hypothetically may represent an added collateral benefit over
single anti-VEGF blocking therapy. Although this finding has not
been confirmed in the intravitreal study groups, this potential
benefit is biologically plausible regarding the inflammatory
conditions of early stages of CNV and must be addressed by
future more rigorous studies, including use of specific inhibitors or
knock-down of cytokines involved in its signalling pathway.
Differences in pSMAD-2 protein levels were obtained in the
intravenous treatment groups and combined P17 and P144
intravitreal group. The unstable nature of TGF-b makes its
biochemical processing difficult and frequently differences can be
overlooked if the primary cytokine is targeted. Therefore, the
understanding of its signalling pathway has pointed the pSMAD-2
as a, although still unstable, more reliable marker. Once the TGF-
b binds its membrane receptor, a signalling cascade activates the
intracellular phosphorylation of SMAD-2 protein, resulting in a
pSMAD-2 protein. The measurement of its levels has been
accepted as an indirect marker for TGF-b activity. The results
obtained in the intravenous groups and intravitreal mixture group
confirmed this TGF-b inhibition, although these results were not
observed in the single peptide intravitreal groups, probably due to
a different pharmacokinetic profile. The effect of the peptides in
extracellular matrix remodelling processes was also remarkable.
Decreased MMP-9 gene expression was observed in both
intravitreal groups and gelatin zymography assays revealed
significantly lower MMP-2 activity in the treated eyes of both
intravenous and intravitreal groups, suggesting a modulatory effect
of both peptides. These findings are especially relevant because
extracellular matrix remodelling is prominent from early to late
CNV lesions, and may represent an additional benefit compared
to current CNV treatments.
A deeper understanding of the different stages of angiogenesis
and their respective growth factors and cellular types is warranted
for the development of new therapies for CNV. Although
intravitreal anti-VEGF results have not been surpassed by any
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other therapy, due to their multifactorial nature, angiogenesis
inhibition alone may not be sufficient to stop the development of
CNV lesions [11–14]. Thus, new approaches may target
mediators involved in CNV at different levels of its etiopathogen-
esis. Whereas in normal eyes TGF-b is a multifunctional regulator
that mediates cellular proliferation, differentiation, apoptotic death
and angiogenesis, the multiple roles played in different CNV stages
suggest that its blockage not only may decrease the angiogenic
process, but also affect other pathways related with the progression
of the lesions to scar tissue formation [10,15–18].
The results reported here reinforce the preliminary results
obtained in our previous study in CNV induction and raise a
significant interest to develop new therapeutic approaches.
However, this study has several limitations. Whereas FA is a
standardized valid method for CNV assessment, the complemen-
tary use of histopathology techniques such as flat mounts may
provide an accurate ex-vivo CNV size estimation to support the in
vivo findings herein reported. In addition, these techniques may be
used to identify and potentially quantify the studied cytokines,
allowing an indirect estimation of their downregulation with the
peptides. These examinations appear extremely interesting and
further studies may be required to confirm or discard the data
reported in this work. Interspecies differences between human and
rat retina, the unaffected RPE of young healthy rats employed, or
interim of time between lesion induction, treatment injection and
sample collection appear as other limitations that may have
affected the results obtained. However, these features may explain
the lack of differences observed in some comparisons, but reinforce
the significant results obtained in others. If laser-induced CNV
reproduces the stages of the wound-healing process and involves
similar growth factors as pathologic CNV, this model may be
useful to assess the peptides effect in early CNV lesions, and
consequently the inhibition of TGF-b by the peptides should be
comparable.
In summary, we report that TGF-b inhibition reduces
progression of early CNV lesions in a laser-induced rat model
and that this reduction is associated with downregulation of
VEGF, TGF-b, COX-2, MMP-2 and MMP-9. The future of
CNV management may require combined therapies with multiple
drugs acting on different mediators involved in CNV progression,
such as VEGF, complement system, TGF-b, PDGF, COX-2,
MMPs and TNFa. In this scenario, the anti-TGF-b peptides
should be considered in this multivariate CNV treatment, but
further studies are needed to assess their effect in established
lesions and especially combined with anti-VEGF drugs, the
current treatment for this condition.
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